LAHORE, JULY 2018:Mirabet(Mirabegron) is the newest addition to the expanding CCL’s urology portfolio;incidentally CCLis the first company to launch Mirabegron in Pakistan. The launch was held in a ceremony at a local hotel in Lahore.
Mirabegron is the most advanced medical treatment for over active bladder. It is an agonist of the human beta – 3 adrenergic receptor (AR). Mirabegron relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill – void cycle by activation of beta – 3 AR, which increases bladder capacity. It is the first and only USFDA approved Beta-3 agonist used to treat symptoms of urinary frequency, urinary urgency andurinary incontinence or leakage due to over active bladder.Overactive bladder is a globally prevalent disease with 14% prevalence in Asia. In Pakistan over 120 million men and women suffer from this disease
